# Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU.

*biotech · news · 2026-05-22 · The Manila Times*

## Key points

- CHMP has recommended approval of Wegovy 7.2 mg single-dose pen for obesity in the EU.
- Novo Nordisk plans to launch Wegovy 7.2 mg single-dose pen in the EU in Q3 2026.
- STEP UP trial showed Wegovy 7.2 mg achieved 20.7% mean weight loss with one-third exceeding 25%.
- Wegovy 7.2 mg single-dose pen is already available in the US and UK under Wegovy HD branding.
- In STEP UP T2D, Wegovy 7.2 mg led to 14.1% weight loss for patients with type 2 diabetes.

**Companies:** Novo Nordisk
**Countries:** Denmark, United States, United Kingdom

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/23/tmt-newswire/globenewswire/novo-nordisk-as-chmp-recommends-eu-approval-of-wegovy-72-mg-in-a-single-dose-pen-providing-up-to-207-mean-weight-loss-1/2350299)

---

Canonical: https://newsio.io/n/0fe52357-af95-4e29-bdf3-930c0e2bba9b/wegovy-7-2-mg-in-a-single-dose-pen-has-now-been-recommended-by-chmp-for-approval
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works